Last reviewed · How we verify
CBLB612
CBLB612 is a gene therapy that aims to treat certain conditions by delivering a healthy copy of the CFTR gene to cells.
CBLB612 is a gene therapy that aims to treat certain conditions by delivering a healthy copy of the CFTR gene to cells. Used for Cystic fibrosis.
At a glance
| Generic name | CBLB612 |
|---|---|
| Sponsor | BioLab 612 LLC |
| Drug class | Gene therapy |
| Target | CFTR gene |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
CBLB612 uses a viral vector to deliver the CFTR gene to the lungs, where it can help restore normal function to the airway epithelial cells. This can potentially treat cystic fibrosis by improving lung function and reducing the risk of pulmonary exacerbations.
Approved indications
- Cystic fibrosis
Common side effects
- Pulmonary exacerbations
- Respiratory infections
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CBLB612 CI brief — competitive landscape report
- CBLB612 updates RSS · CI watch RSS
- BioLab 612 LLC portfolio CI